Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: Comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban

Journal of Pharmacology and Experimental Therapeutics

Volumn 277, Issue 1, 1996, Pages 502-510

  Kawamura, Masaki ^a   Imura, Yoshimi ^a   Moriya, Norihiko ^a   Kita, Shunbun ^a   Fukushi, Hideto ^a   Sugihara, Hirosada ^a   Nishikawa, Kohei ^a   Terashita, Zen Ichi ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA CYCLODEXTRIN; ANTICOAGULANT AGENT; ARGATROBAN; CLOPIDOGREL; FIBRINOGEN; PROSTAGLANDIN E1; TICLOPIDINE; VON WILLEBRAND FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CORONARY ARTERY DILATATION; DISEASE SEVERITY; GUINEA PIG; HUMAN; HUMAN CELL; HUMAN TISSUE; MONKEY; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOGENESIS; THROMBOSIS; VASODILATATION;

ALPROSTADIL; ANIMALS; ASPIRIN; DOGS; FIBRINOLYTIC AGENTS; GUANIDINES; GUINEA PIGS; HUMANS; MACACA FASCICULARIS; MALE; PIPECOLIC ACIDS; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PYRAZINES; TICLOPIDINE;

EID: 0030423699     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. BARKER, P. L., BULLENS, S., BUNTING, S., BURDICK, D. J., CHAN, K. S., DEISHER, T., EIGENBROT, C., GADEK, T. R., GANTZOS, R., LIPARI, M. T., MUIR, C. D., NAPIER, M. A., PITTI, R M., PADUA, A , QUAN, C., STANLEY, M., STRUBLE, M., TOM, J. Y. K. AND BURNIER, J. P. Cyclic RGD peptide analogues as antiplatelet anti-thrombotics J. Med. Chem. 35: 2040-2048, 1992.
2. BECKEE, B. H. AND MILLER, J. L.: Effects of antiplatelet glycoprotein Fb antibody on hemostatic function in the guinea-pig. Blood 74: 690-594, 1989.
3. CHARO, I. F., NANNIZZI, L., PHILLIPS, D. R., HSU, M. A. AND SCARBOROUGH, R. M.: Inhibition of fibrinogen binding to GPIIb/IIIa by a GPIIIa peptide. J. Biol. Chem. 266: 1415-1421, 1991.
4. COOK, N. S , BRUTTGER, O., PALLY, C AND HAGENBACH, A.: The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: Evidence that Ro 43-S857 is orally active. Thromb. Haemostas. 70: 839-847, 1993.
5. COOK, N. S., ZERWES, H.-G , TAPPARELLI, C., POWLING, M , SINGH, J., METTERNICH, R. AND HAGENBACH, A.: Platelet aggregation and fibrinogen binding in human, rhesus monkey, guinea-pig, hamster and rat blood: Activation by ADP and a thrombin receptor peptide and inhibition by glycoprotein IIb/IIIa antagonist. Thromb. Haemostas. 70: 531-539, 1993.
6. EPIC Investigators: Prevention of ischemic complications in high-risk angioplasty by a chimeric monoclonal antibody c7E3 Fab fragment directed against the platelet glycoprotein IIb/IIIa receptor. N. Engl. J. Med. 330: 956-961, 1994.
7. EZRATTY, A. M. AND LOSCALZO, J.: New approaches to antiplatelet therapy. Blood Coagulation and Fibrinolysis 2: 317-327, 1991.
8. 1 in man. J. Clin. Invest. 56: 838-846, 1975.
9. HASS, W. K., EASTON, J. D., ADAMS, JR., H. P., PRYSE-PHILLIPS, W., MOLONY, B. A., ANDERSON, S. AND KAMM, B. (FOR THE TICLOPIDINE ASPIRIN STROKE STUDY GROUP): A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N. Engl. J. Med. 321: 501-507, 1989.
10. HERBERT, J. M., FREHEL, D., VALLEE, E., KIEFFER, G., GOUY, D., BERGER, Y., NECCIARI, J., DEFREYN, G. AND MAFFRAND, J. P.: Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc. Drug Rev. 11:180-198, 1993.
11. 2, ADP and thrombin in thrombogenesis in the guinea pig. Eur. J. Pharmacol. 231: 421-425, 1993.
12. JANG, I. -K., GOLD, H. K., ZISKIND, A. A., LEINBACH, R. C., FALLON, J. T. AND COLLEN, D.: Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation 81: 219-225, 1990.
13. 1 does not accelerate rTPA-induced thrombolysis in acute myocardial infarction. Am. Heart J. 127: 738-743, 1994.
14. MEYER, D. AND GIRMA, J.-P.: von Willebrand factor: Structure and function. Thromb. Haemostas. 70: 99-104, 1993.
15. NICHOLS, A. J., VASKO, J. A., KOSTER, P. F., VALOCIK, R. E., RHODES, G. R., MILLER-STEIN, C., BOPPANA, V. AND SAMANEN, J. M.: The in vivo pharmacological profile of the novel glycoprotein IIb/IIIa antagonist, SK&F 106760. J Pharmacol. Exp. Ther. 270: 614-621, 1994a.
16. NICHOLS, A. J., VASKO, J. A., VALOCIK, R E., KOPACIEWICZ, L. J., STORER, B. L , ALI, F. E., ROMOFF, T., CALVO, R. AND SAMANE, J. M.: The in vitro pharmacological profile of SK&F 106760, a novel GPIIb/IIIa antagonist. Thromb. Res 75: 143-156, 1994b.
17. PEERLINCK, K., DE LEPELEIRE, I., GOLDBERG, M., FARRELL, D., BAERETT, J., HAND, E., PANEBIANCO, D., DECKMYN, H., VERMYLEN, J. AND ARNOUT, J.: MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation 88: 1512-1517, 1993.
18. PHILLIPS, D. R., CHARO, I. F., PARISE, L. V. AND FITZGERALD, L. A.: The platelet membrane glycoprotein IIb/IIIa complex. Blood 71: 831-843, 1988.
19. PLOW, E. F. AND GINSBERG, M. H.: Cellular adhesion: GPIIb/IIIa as a prototypic adhesion receptor. Prog. Hemost. Thromb. 9: 117-156, 1988.
20. SIMS, P. J., FAIONI, E. M., WIEDMER, T. AND SHATTIL, S. J.: Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J. Biol. Chem. 263: 18205-18212, 1988.
21. WALSH, P. N., BAGLIA, F. A. AND JAMESON, B. A.: Factor XI and platelets Activation and regulation. Thromb. Haemostas. 70: 75-79, 1993.